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Background: Paediatric Multisystem Inflammatory Syndrome temporally associated with SARS-CoV-2 (PIMS-
TS), first identified in April 2020, shares features of both Kawasaki disease (KD) and toxic shock syndrome
(TSS). The surveillance describes the epidemiology and clinical characteristics of PIMS-TS in the United King-
dom and Ireland.
Methods: Public Health England initiated prospective national surveillance of PIMS-TS through the British
Paediatric Surveillance Unit. Paediatricians were contacted monthly to report PIMS-TS, KD and TSS cases
electronically and complete a detailed clinical questionnaire. Cases with symptom onset between 01 March
and 15 June 2020 were included.
Findings: There were 216 cases with features of PIMS-TS alone, 13 with features of both PIMS-TS and KD, 28
with features of PIMS-TS and TSS and 11 with features of PIMS-TS, KD and TSS, with differences in age, eth-
nicity, clinical presentation and disease severity between the phenotypic groups. There was a strong geo-
graphical and temporal association between SARS-CoV-2 infection rates and PIMS-TS cases. Of those tested,termeasures Division, Public
hani).
er Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
2 J. Flood et al. / The Lancet Regional Health - Europe 3 (2021) 10007514.8% (39/264) children had a positive SARS-CoV-2 RT-PCR, and 63.6% (75/118) were positive for SARS-CoV-2
antibodies. In total 44¢0% (118/268) required intensive care, which was more common in cases with a TSS
phenotype. Three of five children with cardiac arrest had TSS phenotype. Three children (1¢1%) died.
Interpretation: The strong association between SARS-CoV-2 infection and PIMS-TS emphasises the impor-
tance of maintaining low community infection rates to reduce the risk of this rare but severe complication in
children and adolescents. Close follow-up will be important to monitor long-term complications in children
with PIMS-TS.
Funding: PHE.
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Evidence before this study
We searched Embase, Medline, Scopus, medRxiv, bioRxiv and
Google for articles on PIMS-TS or Multisystem Inflammatory
Syndrome in Children (MIS-C) during the COVID-19 pandemic.
The search was for papers published from 01 Jan 2020, and no
language restrictions were applied. A full list of search terms
are listed in Supplementary Material 1, but in brief, search
terms were (“SARS” OR “COVID” OR “coronavirus” or “nCoV”)
AND (“kawasaki” OR “hyper inflammatory” OR “cytokine” OR
“lymph node syndrome” OR “toxic shock” OR “PIMS-TS” OR
“MIS-C” OR “TSS”) AND (“infant” OR “child” OR “adolescent” OR
“minors” OR “puberty” OR “paediatrics” OR “pediatrics”). We
identified 10 relevant studies (combined N = 847), in which:
12100% cases had cardiovascular involvement, 42100% had
gastrointestinal involvement, and 1356% had neurological
involvement. In these studies, 962% required mechanical ven-
tilation, 21100% required admission to intensive care, and
04% died. Where reported, 2075% cases were SARS-CoV-2
PCR positive, and 3390% were SARS-CoV-2 serology positive.
Criteria for KD were fulfilled in 4100% of cases in reported
studies, although this was sometimes an inclusion criteria.
Added value of this study
This study provides information on a large prospective cohort
of children with PIMS-TS. There was a regional association
between trends in SARS-CoV-2 incidence and PIMS-TS reports
by lower tier Local Authorities, providing additional evidence
of an epidemiological link between the syndrome and SARS-
CoV-2. While signs and symptoms are comparable to other
studies, we also characterise different phenotypes of case pre-
sentations using Latent Class Analysis, which broadly agreed
with findings reported by United States Centers for Disease Pre-
vention and Control (CDC).
Implications of all the available evidence
The strong temporal association between SARS-CoV-2 infection
and PIMS-TS emphasises the importance of maintaining low
community infection rates to reduce the risk of this rare but
severe complication in children and adolescents. Based on the
reported cases that did not fulfil the PIMS-TS criteria, we pro-
pose that an elevated C-Reactive Protein is not a sensitive crite-
rion for syndromic diagnosis.
1. Introduction
Children make up only a small proportion of coronavirus disease
2019 (COVID-19) cases, hospitalisations or deaths. [1] Severalcountries in Europe, [2-8] the Americas [9-12] and Asia [13-15] have,
however, reported cases of a rare Paediatric Inflammatory Multisys-
tem Syndrome temporally associated with SARS-CoV-2 (PIMS-TS).
The symptoms and signs are similar to both Kawasaki disease (KD)
and toxic shock syndrome (TSS), and are typically characterised by
single- or multi-organ dysfunction, although less serious presenta-
tions, such as abdominal pain, vomiting and diarrhoea have also been
reported. [12] The first reports of KD-/TSS-like presentations with
COVID-19 first emerged in April 2020, [16, 17] and PIMS-TS cases
have since been reported globally. [18] In the United States, where
PIMS-TS is termed Multisystem Inflammatory Syndrome in Children
(MIS-C), 1659 cases and 26 deaths were reported by 08 January 2021.
[12] In Europe and elsewhere, most PIMS-TS reports have been lim-
ited to small case series with varying case definitions. Following the
first reports of PIMS-TS cases in London, England, [16] Public Health
England (PHE) initiated enhanced prospective national surveillance
of PIMS-TS, along with KD and TSS, in the United Kingdom (UK) and
the Republic of Ireland through the British Paediatric Surveillance
Unit team (BPSU). Here we present the epidemiology, temporal and
geographical association with SARS-CoV-2 incidence, clinical and
analytical findings, and outcomes of the first tranche of cases
reported up until 24 July 2020.2. Methods
2.1. Literature review
A literature search was conducted to compare the BPSU data with
other similar scale studies of PIMS-TS cases published to date
(Supplementary Material 1).2.2. Data collection
This study was conducted through the BPSU of the Royal College
of Paediatrics and Child Health (RCPCH), a unit established three dec-
ades ago to study rare paediatric diseases. Paediatricians across the
UK and Ireland receive monthly email requests to report cases of rare
conditions listed on the “Orange Card”, including nil returns. Around
90% of paediatricians complete the Orange Card each month. [19]
PIMS-TS was added to the Orange Card from 04 May 2020 onwards,
and paediatricians reporting cases were contacted to complete an
electronic questionnaire regarding demographics, concurrent medi-
cal conditions, symptoms, signs, investigations, laboratory results
and treatments.2.3. Case definitions
The BPSU reporting case definition was purposely broad to cap-
ture all potential cases and included children aged <16 years, with
illness onset from 01 March 2020, who had PIMS-TS, [20] typical/
atypical KD, [21] or typical/atypical TSS, [22] regardless of SARS-CoV-
2 status (Table 1, Supplementary Material 2).
Table 1
Definitions of PIMS-TS, KD, TSS used for analysis of cases.
As per the RCPCH definition, [20] PIMS-TS cases were defined as patients with:
1) Fever >38 °C; and,
2) CRP >100 mg/L; and,
3) One or more of the following:
a. Cardiac involvement (any one of the following):
i. Myocarditis/pericarditis/valvulitis; or,
ii. coronary artery involvement (echo); or,
iii. cardiac failure/arrest.
b. Gastrointestinal involvement (any one of the following):
i. vomiting/diarrhoea; or,
ii. an acute abdomen; or,
iii. abnormal liver function (LFTs/clotting).
c. Respiratory failure (requiring any one of the following):
i. high flow and humidified oxygen (HFHO); or,
ii. CPAP; or,
iii. Ventilation.
d. Raised Ferritin (>500ug/L) +/- Raised D-dimers (>2x upper limit normal)
4) And no pathogen (except SARS-CoV-2*) or diagnosis (e.g. confirmed appendici-
tis)
KD was defined according to the criteria set out in McCrindle et al. (2017): [21]
having fever duration >4 days and at least four of the following signs:
1) Conjunctivitis (bilateral, bulbar, non-suppurative)
2) Lymphadenopathy (cervical >15 cm diameter)
3) Rash (widespread, polymorphous, not vesicular)
4) Lips and mucosa (red cracked lips, strawberry tongue, erythematous oral cav-
ity)
5) Changes of extremities (erythema, oedema of palms and soles initially)





5) Multisystem involvement  3 or more of:
a. Gastrointestinal: vomiting or diarrhoea
b. Muscular: elevated creatine kinase (600 U/L) and/or muscle aches
c. Mucous membrane: conjunctivitis
d. Central nervous system: confusion
e. Haematologic: platelets <100 £ 109/L
f. Renal: abnormal creatinine (over 2x upper limit of normal) For <4yrs
78 umol/L, 511 years 106 umol/L, 1215 years 180 umol/L
g. Hepatic: abnormal ALT (over 2x upper limit of normal), so 82 IU/L if <1
year, 56 IU/L if 12 years, 58 if 36 years, 72 IU/L if 712 years,
74 IU/L if 1315 years
* Current or past infection with SARS-CoV-2 was explicitly not an inclusion require-
ment
ALT Alanine transaminase; CRP C-reactive Protein; KD Kawasaki disease; LFT Liver
function test; PIMS-TS Paediatric Inflammatory Multisystem Syndrome temporally
associated with SARS-CoV-2; RCPCH Royal College of Paediatrics and Child Health; TSS
Toxic shock syndrome.
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Reported cases were categorised according to criteria for indi-
vidual syndromes. Descriptive analysis was undertaken in STATA
v.15.0 (StataCorp, Tx). Since case numbers in most categories
were small, P-values were not calculated in comparisons between
categories. The geographic distribution of PIMS-TS cases was
compared to SARS-CoV-2 infection rates per 10,000 population by
lower tier local authority. Only qualitative analysis was per-
formed because PIMS-TS rates at local authority level were too
low to make meaningful quantitative comparisons. Geographical
analysis was performed in Python using the GeoPandas (v.0.8.1)
package alongside ArcMap software (ESRI). Temporal analysis was
performed using published national and regional SARS-CoV-2
infection rates in England. [23] Lag time was defined as the num-
ber of days between peak regional SARS-CoV-2 incidence and
peak PIMS-TS cases. Mean weight by age and sex data [24] were
used to calculate Z-scores [=(value-population mean)/population
SD] and identify children who were overweight (2 standard devi-
ations (SDs) above their mean weight for age and sex).2.5. Latent class analysis
Latent Class Analysis (LCA) aims to define unobserved groups of
cases within the data, based on indicator (yes/no) variables. The
method identifies possible clustering models which group cases into
distinct latent classes. The fit of each model is assessed using a Bayes-
ian Information Criterion score, with the best fitting model being the
one which minimises this score. The selected model provides a condi-
tional probability for membership of the identified latent classes,
given the ‘yes/no’ value of each indicator variable. The R package
poLCA (v.1.4.1) was used to identify latent classes based on the 23
indicator variables corresponding to the PIMS-TS, KD and TSS defini-
tions, along with variables confirming SARS-CoV-2 infection by RT-
PCR or serology (Supplementary Material 3).3. Results
3.1. Literature review
Data from ten published studies are summarised alongside the
BPSU dataset in Tables S1.2 and S1.3.3.2. BPSU surveillance
There were 449 cases reported to BPSU. Eighty-nine duplicates
were removed, 12 were 16 years old and five had onset dates pre-
01 March 2020. This left 343 cases with illness onset between 01
March and 15 June 2020; 268 were classified as PIMS-TS and included
in the analysis (Fig. 1a). The remaining 75 cases included 56 cases
that did not fulfil the PIMS-TS, KD or TSS criteria (35 because of C-
reactive protein (CRP) <100 mg/L, eight because CRP level was miss-
ing; 13 lacked other criteria), 13 with KD only, two with TSS only and
four with KD/TSS.
Of the PIMS-TS cases, 246 were in England, six in Scotland, 11 in
Wales, two in Northern Ireland, and three in the Republic of Ireland.
Cases were categorised based on pre-defined syndromic criteria
(Fig. 1b) and included 216 cases classified as PIMS-TS only without
features of KD or TSS, 13 with PIMS-TS and complete/typical KD
(PIMS-TS/KD), 28 cases with PIMS-TS and TSS (PIMS-TS/TSS) and 11
with all three phenotypes (PIMS-TS/KD/TSS). Data are presented for
all 343 children by phenotype (Supplementary Material 4). Two cases
were classified as TSS only, and four as KD and TSS; these were
included in total cases only.3.3. Demographics
The median age of cases was 8¢2 (IQR 4¢012¢1) years, with PIMS-
TS/KD cases being younger (5.2 years) and PIMS-TS/TSS cases older
(8¢8 years) than PIMS-TS only cases (7¢8 years; Table 2). Males were
over-represented in all categories, 19¢0% (51/268) had co-morbid-
ities, and 13¢4% (36/268) were overweight. Although the numbers of
children with multiple syndromes were small, a higher proportion of
PIMS-TS/KD and PIMS-TS/TSS cases were Asian (46¢2% and 42¢9%,
respectively) or Black (23¢1% and 35¢7%, respectively), while White
children were underrepresented (15¢4% and 14¢3%, respectively)
compared to PIMS-TS only cases where 48¢6% were White, 20¢4%
Asian and 19¢4% Black. Of the 63 cases in Asian children, 50 were
from the Indian subcontinent (Bangladeshi/Indian/Pakistani/Nepali/
Sri Lankan/Afghani), one was East Asian and ten did not have addi-
tional information. Parental occupation was reported for 105 cases
and 77¢1% had a healthcare (39¢0%; n = 41) or non-healthcare key-
worker (38¢1%; n = 40) parent.
Fig. 1a. (a) Diagram showing cases submitted to BPSU through to those used in the final analysis. (b) Venn diagram showing overlap of PIMS-TS/Kawasaki/TSS case definitions.
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Presenting symptoms by category are presented in Supplementary
Material 4. PIMS-TS/KD/TSS cases had the highest proportion with
cough, sore throat, pale/mottled skin and neurological involvement
(Table S4.2), while >80% of PIMS-TS/TSS cases had hypotension or
required fluid boluses  higher than other phenotypes. Cases meeting
the TSS criteria had higher rates of: abdominal pain, vomiting, diar-
rhoea, respiratory involvement, cold hands/feet, age-specific tachycar-
dia and urinary output <2 ml/kg/hr. Additionally, a widespread,polymorphous (not vesicular) rash (82¢1%) and conjunctivitis (82¢1%)
were frequently reported for PIMS-TS/TSS cases but were less common
among PIMS-TS only cases (32¢9% and 40¢7%, respectively).
Where tested, ST or T wave changes were the most common ECG
findings (14¢7%; 24/163) (Table S4.4). None of the children had a
myocardial infarction but five had a cardiac arrest: 10¢7% (3/28)
PIMS-TS/TSS cases and 0¢9% (2/216) PIMS-TS only cases. Of the cases
that had an echocardiogram, 38¢4% (78/203) had decreased myocar-
dial contractility, 26¢6% (54/203) had coronary artery abnormalities
(dilation/aneurysm), 20¢2% (41/203) had pericardial effusion and
Table 2
Demographic features of cases presenting with PIMS-TS, with illness onset after 1st March 2020.
Total with any PIMS PIMS-TS only PIMS-TS/KD PIMS-TS/TSS PIMS-TS/ KD/ TSS
n (%) n (%) n (%) n (%) n (%)
Total 268 (100¢0%) 216 (100¢0%) 13 (100¢0%) 28 (100¢0%) 11 (100¢0%)
Sex
Male 161 (60¢1%) 124 (57¢4%) 11 (84¢6%) 21 (75¢0%) 5 (45¢5%)
Female 90 (33¢6%) 79 (36¢6%) 2 (15¢4%) 5 (17¢9%) 4 (36¢4%)
Age group
<1 year 23 (8¢6%) 19 (8¢8%) 2 (15¢4%) 2 (7¢1%) 0 (0¢0%)
14 years 65 (24¢3%) 54 (25¢0%) 4 (30¢8%) 4 (14¢3%) 3 (27¢3%)
59 years 80 (29¢9%) 61 (28¢2%) 4 (30¢8%) 10 (35¢7%) 5 (45¢5%)
1015 years 100 (37¢3%) 82 (38¢0%) 3 (23¢1%) 12 (42¢9%) 3 (27¢3%)
Median age (IQR) 8¢21 years (4¢0312¢09) 7¢84 years (4¢0312¢60) 5¢19 years (1¢859¢75) 8¢83 years (6¢1512¢32) 7¢09 years (4¢3210¢07)
Weight 2 SDs above mean for age/
sex
36 (13¢4%) 32 (14¢8%) 0 (0¢0%) 1 (3¢6%) 3 (27¢3%)
Underlying medical conditions
Any 51 (19¢0%) 43 (19¢9%) 2 (15¢4%) 2 (7¢1%) 4 (36¢4%)
Neurodevelopmental 12 (4¢5%) 10 (4¢6%) 2 (15¢4%) 0 (0¢0%) 0 (0¢0%)
Gastrointestinal 7 (2¢6%) 6 (2¢8%) 0 (0¢0%) 0 (0¢0%) 1 (9¢1%)
Haematological 7 (2¢6%) 4 (1¢9%) 0 (0¢0%) 0 (0¢0%) 3 (27¢3%)
Asthma requiring regular medication 6 (2¢2%) 6 (2¢8%) 0 (0¢0%) 0 (0¢0%) 0 (0¢0%)
Ethnicity
White 114 (42¢5%) 105 (48¢6%) 2 (15¢4%) 4 (14¢3%) 3 (27¢3%)
Black/ African/ Caribbean/ Black
British
60 (22¢4%) 42 (19¢4%) 3 (23¢1%) 10 (35¢7%) 5 (45¢5%)
Asian/ Asian British 63 (23¢5%) 44 (20¢4%) 6 (46¢2%) 12 (42¢9%) 1 (9¢1%)
Mixed/ multiple ethnic groups 11 (4¢1%) 9 (4¢2%) 1 (7¢7%) 0 (0¢0%) 1 (9¢1%)
Other ethnic groups 10 (3¢7%) 8 (3¢7%) 0 (0¢0%) 1 (3¢6%) 1 (9¢1%)
Outcome
Admitted to PICU 118 (44¢0%) 89 (41¢2%) 4 (30¢8%) 19 (67¢9%) 6 (54¢5%)
Required conventional ventilation/
High Frequency Oscillation
44 (16¢4%) 28 (13¢0%) 1 (7¢7%) 10 (35¢7%) 5 (45¢5%)
Required peritoneal dialysis 1 (0¢4%) 1 (0¢5%) 0 (0¢0%) 0 (0¢0%) 0 (0¢0%)
Required inotropes 80 (29¢9%) 56 (25¢9%) 3 (23¢1%) 15 (53¢6%) 6 (54¢5%)
Died 3 (1¢1%) 2 (0¢9%) 0 (0¢0%) 1 (3¢6%) 0 (0¢0%)




















IQR Interquartile Range; n Number of cases; PICU Paediatric Intensive Care Unit; SD Standard Deviation.
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Pericardial effusion and mitral or aortic valve insufficiency were
more common among PIMS-TS cases associated with another syn-
drome.3.5. SARS-CoV-2 testing
Nearly all cases (264/268, 98.5%) had an RT-PCR test for SARS-
CoV2 infection but only 44¢0% (118/268) had SARS-CoV-2 serology.
Of those tested, 14¢8% (39/264) children were RT-PCR positive and
63¢6% (75/118) were seropositive. Overall, 35¢1% (94/268) had evi-
dence of current or previous SARS-CoV-2 infection (Table S4.5).
Where reported, 46¢6% (125/268) had a positive SARS-CoV-2 test or a
household contact with confirmed SARS-CoV-2 or COVID-19-like
symptoms in the 4 weeks prior to illness (Table S4.5).3.6. Laboratory findings
PIMS-TS/TSS cases had higher values of CRP, D-dimers, ferritin,
INR, NT-proB-type Natriuretic Peptide and fibrinogen, and PIMS-TS/
TSS and PIMS-TS/KD/TSS cases had higher values of triglycerides,
amylase, creatine kinase, urea, creatinine, neutrophils, and ALT (Table
S4.7). Most cases had low albumin (86¢9%), with PIMS-TS/TSS and
PIMS-TS/KD/TSS cases having lower values than other presentations.
For all PIMS-TS cases, where reported, the median (IQR) CRP was 223
(162289) mg/L, ferritin 543 (2841049) ug/L, and D-dimers 3400
(17576921) ug/L.3.7. Treatment
92¢9% (249/268) cases were reported to have received antibiotics,
73¢1% (196/268) aspirin/other anticoagulant, 55¢6% (149/268) ste-
roids, 70¢5% (189/268) immunoglobulins, and 6¢7% (18/268) antivi-
rals. Ten (3¢7%) children each received monoclonal antibodies against
TNF-a and an interleukin-1 receptor antagonist, respectively, one
other child received both (0¢4%), and four others (1¢5%) received
monoclonal antibodies against the interleukin-6 receptor.3.8. Outcomes
In total, 44¢0% (118/268) children were admitted to a Paediat-
ric Intensive Care Unit (PICU) (Table 2), which was proportion-
ately more common among cases meeting TSS criteria (67¢9% [19/
28] with PIMS-TS/TSS, 54¢5% [6/11] with PIMS-TS/KD/TSS). This
group was also more likely to require conventional ventilation or
high frequency oscillation (35¢7% PIMS-TS/TSS, 45.5% PIMS-TS/KD/
TSS) than PIMS-TS only (13¢0%) or PIMS-TS/KD (7¢7%), as well as
inotropes  just over half of cases, compared to around a quarter
of PIMS-TS only or PIMS-TS/KD cases. Three children died (all
male), accounting for 3¢6% (1/28) with PIMS-TS/TSS and 0¢9% (2/
216) with PIMS-TS only. Two had underlying comorbidities
(anorexia and obesity, respectively). One was an infant and the
other two were aged 1015 years. The cause of death included
stroke, ruptured coronary aneurysm and invasive fungal infection
secondary to bone marrow suppression.
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In terms of clinician-reported syndromes, 68¢1% (147/216) PIMS-
TS only cases were reported as suspected PIMS-TS only, with 29
remaining cases reported as suspected PIMS-TS plus TSS or KD
(Supplementary Material 5).
3.10. Time and place
Overall, 46¢3% (124/268) of cases were reported from Greater Lon-
don (Table S4.10). The most notable difference was ethnicity distribu-
tion: 35¢3% of Greater London cases were Black and 27¢6% White
compared to 13¢4% and 57¢7% cases, respectively, outside London.
Cases within London were also older with 5¢6% under 1 year and
46¢0% 1015 years, compared to 11¢1% and 29¢9%, respectively, out-
side London.
3.10.1. Geographic analysis
Geographic analysis identified clustering with Lower Tier Local
Authorities (LTLAs) reporting higher numbers of confirmed COVID-
19 cases per 10,000 population up to 01 July 2020 (Fig. 2a). There
was no association with population size, or regions with the highest
COVID-19 prevalence (London, the West Midlands and the North-
West). Smaller urban areas with high COVID-19 prevalence (Leices-
ter, Luton) reported more cases than other cities of similar size with
COVID-19 rates (Nottingham, York). Notably, too, the South West, a
region with low COVID-19 incidence, reported relatively more cases
during the surveillance period.
3.10.2. Temporal analysis
Temporal analysis found the 246 PIMS-TS cases in England fol-
lowed the epidemic curve of COVID-19 in the English regions, as
defined by the Public Health England Centres (PHECs), between
March and July 2020 with a median lag of approximately 16¢3 (IQR
923) days, although this varied between PHECs (Figs. 2b and 2c).
Notable were reports of cases from the East of England, East Midlands
and the South West during periods of low regional COVID-19 preva-
lence.
3.11. Latent class analysis
Fig. 2d shows a graphical representation of the different classes
identified by LCA, and the probability of membership conditioned on
each indicator variable. Class 1 (n = 75) consisted solely of PIMS-TS
only cases; Class 2 (n = 88) contained 66¢7% (16/24) of cases that met
KD criteria; Class 3 (n = 105) contained 61¢5% (24/39) of cases that
met TSS criteria (Table 3). Ethnicity distributions varied between the
groups, with Black, Asian, Mixed and Other ethnicities accounting for
only 40¢0% cases in Class 1 (13¢3% Black, 17¢3% Asian), 53¢4% in Class
2 (15¢9% Black, 26¢1% Asian), and 73¢7% in Class 3 (34¢3% Black, 25¢7%
Asian). Additionally, the median age of cases in Class 2 was 4¢5 (IQR
1¢57¢5) years, compared to 7¢8 (IQR 3¢111¢2) years in Class 1 and
11¢2 (IQR 8¢413¢9) years in Class 3.
Class 1 cases had the least severe presentations, with a lower pro-
portion reporting dermatological/cardiac/haematological/neurologi-
cal involvement, compared to other syndromes. This group did have
high proportions with vomiting/diarrhoea (65¢3%), abdominal pain
(60¢0%), hypoalbuminaemia (66¢7%), and raised D-dimers (54¢7%),
although these were all more prevalent in Class 3 cases. Only 14¢7%
(11/75) reported a cough and, while 25¢3% (19/75) reported tachyp-
noea, none required respiratory support.
Class 2 cases had the highest proportions with dermatological
involvement, with >75% having KD features of rash, conjunctivitis or
lips/mucosa signs. This group also had 68¢2% (60/88) presenting with
vomiting/diarrhoea, and 88¢6% (78/88) had hypoalbuminaemia.Cough (34¢1%; 30/88) was relatively more common, while abdominal
pain (33¢0%; 29/88) less common. One case died.
Class 3 cases had the most severe disease, with the highest pro-
portions having multi-organ involvement. Their median duration of
hospitalisation was 9¢5 days (IQR 813) compared to 5 days (IQR
48) and 6 days (IQR 411) in Classes 1 and 2, respectively. There
were two deaths in Class 3.
4. Discussion
Enhanced prospective national surveillance identified 268 cases
that fulfilled a broad case definition for PIMS-TS since the start of the
COVID-19 pandemic in the UK and Ireland. These included 216 with
PIMS-TS only, 13 PIMS-TS/KD, 28 PIMS-TS/TSS and 11 PIMS-TS/KD/
TSS. Cases differed in age, ethnicity, clinical presentation, cardiovas-
cular involvement and disease severity. Children classified as PIMS-
TS and another syndrome were more likely to require intensive care
support and longer hospitalisation stay than those with PIMS-TS
only. There was a temporal and geographical association between
community SARS-CoV-2 prevalence and PIMS-TS cases, both nation-
ally and regionally, with a median lag of 16 days between COVID-19
and PIMS-TS cases in England. LCA identified three different classes
which broadly divided into PIMS-TS only (Class 1), PIMS-TS/KD (Class
2) and PIMS-TS/TSS (Class 3), with Class 2 cases tending to be youn-
ger, and Class 3 older.
The age distribution of cases (median 8.2 years; IQR 4.012.1
years) was similar to that described in other large [9, 10] and smaller
[3-5, 14, 15] case series, and this included the 570 cases described by
Godfred-Cato et al. [10] (median 8 years; IQR 412 years) that
included cases up to 20 years of age. In common with most other
cohorts, males were overrepresented. [3, 7, 9-11] The percentage of
patients with comorbidities and/or overweight was largely similar to
reported studies (Table S1.2), although a smaller percentage had
comorbidities in Latin America [9] and India, [15] and a greater pro-
portion were obese in the US. [10] The low case fatality rate was also
consistent with the international literature (Table S1.2).
The percentage of white children with PIMS-TS in our cohort
(42¢5%) was higher than in the US (13¢2%) [10] or France (Paris, 25¢0%),
[8] where higher proportions of Hispanic and/or Black ethnicities were
reported, likely reflecting the ethnic diversity of their respective popu-
lations. Nonetheless, Black and Asian ethnicities in our cohort were
hugely over-represented relative to the UK population, [25] and
accounted for a disproportionate proportion with the most severe pre-
sentations. Although this may in part be due to London having the
highest COVID-19 infection rate in the first wave, it may also be due to
overrepresentation of these ethnicities among key workers and lower
socioeconomic groups: both at increased risk of COVID-19.
Notably, Asian children other than from the Indian Subcontinent,
who are known to be increased risk of KD, appeared to be under-repre-
sented among PIMS-TS cases. Whether the observed ethnic disparities
among children with PIMS-TS, as observed with COVID-19 cases too,
are due to genetic or socio-economic risk factors or both remains to
be established. [26]
SARS-CoV-2 infection was confirmed by RT-PCR in 14¢8% of PIMS-
TS cases. Although some studies reported similarly low PCR-positivity
rates, [4, 9, 15] most reported higher positivity rates (38¢175¢0%). [3,
5, 7, 8, 10, 11, 14] The large variation is likely due to test availability
in addition to case definitions, since the US MIS-C definition, used by
several studies, required confirmed SARS-CoV-2 infection or known
exposure. [3, 9-11, 14] However, SARS-CoV-2 antibody-positivity
(63¢6%) was similar to the reported range (50¢090¢5%), [3-5, 7-11]
although only 44¢0% in our cohort were tested for SARS-CoV-2 anti-
bodies.
The following rates of system involvement were within the ranges
reported in the literature: (a) 52% with cardiovascular involvement (vs.
12100% in the literature) (b) 99% with gastrointestinal involvement (vs.
a
Fig. 2a. A map of all BPSU reports of PIMS-TS cases in England with postcode information (n = 246), alongside the rate of COVID-19 cases in LTLAs in England up to the 1st of July.
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[3-5, 7-11, 14, 15] Despite the BPSU case definition not being limited
to those with confirmed SARS-CoV-2 infection or known COVID-19
exposure, the distribution of symptoms was broadly similar to the
US report: [10] 53% (UK) vs. 55% (USA) with rash, 50% vs. 48% con-
junctival injection, 99% vs. 91% gastrointestinal involvement, 32% vs.
38% neurological involvement, 26% vs. 29% cough, 16% vs. 13%
requiring mechanical ventilation, 9% vs. 5% with complete KD; the
main differences being a lower proportion with cardiovascular
involvement and ICU admission in our cohort (Table S1.3).
LCA validated the findings of the different phenotypes in our
cohort and identified three separate classes which broadly defined
patients with PIMS-TS only, those with KD features and a third groupwith TSS manifestations. Such characterisations are likely to be useful
for clinical management of children presenting with such a wide syn-
drome. The Class 3 patients, for example, had very high proportions
with cardiac involvement, vomiting/diarrhoea, abdominal pain,
hypotension, low albumin, and raised D-dimers and ferritin, were
older, as well as the highest proportions with positive SARS-CoV-2
PCR or antibody, and were most likely to present with multiorgan
failure requiring inotropic support and assisted ventilation. In con-
trast, Class 2 patients had more typical KD features, while Class 1
patients had features of PIMS-TS only and a milder course of illness.
These findings are similar to the LCA analysis performed in US chil-
dren, where Classes 2 and 3 corresponded to their Classes 3 and 1,
respectively. [10] [27, 28]
b
Fig. 2b. Confirmed COVID-19 cases by PHECs alongside PIMS-TS cases by week of onset. Note different y-axes used. Left axes for confirmed COVID-19 cases, right axes for PIMS-TS
cases.
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clinician and was, therefore, more likely to be undertaken for more
severe cases. Whilst most children had favourable cardiovascular
outcomes, the clinical presentation of five children with cardiac
arrest and the need for inotropes in a significant proportion of cases
suggests that such children need careful cardiovascular assessment,
[27, 28] even after recovery to assess their risk of long-term compli-
cations as has been reported for KD. [21, 29]
Current epidemiological evidence strongly indicates an associa-
tion between SARS-CoV-2 infection and PIMS-TS 24 weeks later. [2,
12] In our cohort, a substantial proportion of tested children were
SARS-CoV-2 RT-PCR and antibody negative. This could be because
PIMS-TS occurred in the cusp between elimination of the virus and
antibody development. The mechanism by which SARS-CoV-2 infec-
tion leads to PIMS-TS is unknown but would provide useful insight
into the pathogenesis of both KD and TSS which have remained elu-
sive so far. It also remains unclear whether PIMS-TS and KD represent
a continuum of illness or are completely distinct syndromes. [30] A
recent study reported similar immune and plasma protein profiles
but different autoantibody targets among KD and PIMS-TS cases,
although the sample size was small. [31]
20,26In our surveillance, 35 children had PIMS-TS features but
did not meet the case definition only because their CRP level was
below the arbitrary 100 mg/L cut-off. It is likely that these were
milder cases along the PIMS-TS spectrum, which needs to be taken
into account in future case definitions. As the number of reported
cases continue to increase worldwide, it is important to reach a
consensus in naming and case definitions so that the data are more
comparable between countries and across continents. We pur-
posely opted for a broad reporting case definition to capture as
many cases as possible but needed to define boundaries to reduce
the reporting of non-PIMS-TS cases. We also asked clinicians to
report TSS and KD cases that were not associated with SARS-CoV-2
for comparison, but there were very few such cases reported for
comparison. As ours was a paediatric study, we also limited oursurveillance to <16 year-olds who would be managed by paedia-
tricians since, in the UK and Ireland, older children and adults
would typically present to adult services. [32] Additionally, the
BPSU methodology requires paediatricians to report cases to the
investigators. Mild cases and those that were not hospitalised or
had short hospital stays may, therefore, be missed. Also, since so
many reported cases were SARS-CoV-2 negative, it possible that
some KD and TSS cases might have been misclassified as PIMS-TS.
Moreover, the BPSU was also the only source of reporting; we
therefore, cannot comment on the completeness of case ascertain-
ment, especially in nations that reported very few cases. After
reporting a case, paediatricians completed a questionnaire using
the information documented in the medical records, so some data,
such as the child’s height or parental occupation, for example, may
not be documented. Finally, the investigation and treatment of
cases was at the discretion of the clinician and, therefore, variable
both geographically and over time with increasing recognition,
knowledge and experience with managing PIMS-TS cases.
5. Conclusions
The strong association between SARS-CoV-2 and PIMS-TS
emphasises the importance of maintaining low community
infection rates to reduce the risk of PIMS-TS. Understanding the
relationship between SARS-CoV-2 infection and PIMS-TS could
provide useful insight into the pathogenesis of both KD and TSS.
Close follow-up will be important to monitor rapidly changing epi-
demiology as well as the short- to long-term complications in chil-
dren with PIMS-TS.
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Table 3
Characteristics of classes identified in the latent class analysis.
Class 1 (N = 75) Class 2 (N = 88) Class 3 (N = 105) P value
Positive SARS-CoV-2 PCR test (N = 39) 6 (8¢0%) 4 (4¢5%) 29 (27¢6%) <0¢01
Positive SARS-CoV-2 serology test (N = 75) 8 (10¢7%) 22 (25¢0%) 45 (42¢9%) <0¢01
Median Age (IQR) in years 7¢8 (3¢111¢2) 4¢5 (1¢57¢5) 11¢2 (8¢413¢9)
Median Hospital Stay (IQR) in days 5 (48) 6 (411) 9¢5 (813)
Weight 2 SDs above mean for age/sex 11 (14¢7%) 4 (4¢5%) 21 (20¢0%) <0¢01
Ethnicity
White 45 (60¢0%) 41 (46¢6%) 28 (26¢7%) <0¢01
Black/ African/ Caribbean/ Black British 10 (13¢3%) 14 (15¢9%) 36 (34¢3%) <0¢01
Asian/ Asian British 13 (17¢3%) 23 (26¢1%) 27 (25¢7%) <0¢01
Mixed/ multiple ethnic groups 3 (4¢0%) 5 (5¢7%) 3 (2¢9%) <0¢01
Other ethnic groups 1 (1¢3%) 3 (3¢4%) 6 (5¢7%) <0¢01
Cardiovascular Involvement
Any cardiac arrest or findings on ECG/Echo 18 (24¢0%) 39 (44¢3%) 83 (79¢1%) <0¢01
Hypotension 14 (18¢7%) 16 (18¢2%) 84 (80¢0%) <0¢01
Dermatological Involvement
Kawasaki-type rash (widespread, polymorphous, not vesicular) 3 (4¢0%) 74 (84¢1%) 40 (38¢1%) <0¢01
Other rash 6 (8¢0%) 21 (23¢9%) 22 (21¢0%) 0¢06
Conjunctivitis (bilateral, bulbar, non-suppurative) 5 (6¢7%) 74 (84¢1%) 56 (53¢3%) <0¢01
Kawasaki lips and mucosa (red cracked lips, strawberry tongue, erythematous oral cavity) 2 (2¢7%) 67 (76¢1%) 20 (19¢0%) <0¢01
Gastrointestinal Involvement
Vomiting/diarrhoea 49 (65¢3%) 60 (68¢2%) 87 (82¢9%) 0¢01
Abdominal pain 45 (60¢0%) 29 (33¢0%) 78 (74¢3%) <0¢01
Low albumin 50 (66¢7%) 78 (88¢6%) 104 (99¢1%) <0¢01
Raised ALT 10 (13¢3%) 22 (25¢0%) 57 (54¢3%) <0¢01
Raised D-dimers 41 (54¢7%) 46 (52¢3%) 96 (91¢4%) <0¢01
Haematological Involvement
Low platelets (<100 £ 109/L) 7 (9¢3%) 9 (10¢2%) 38 (36¢2%) <0¢01
Neurological Involvement
Headache 16 (21¢3%) 13 (15¢3%) 32 (30¢5%) 0¢03
Seizure 1 (1¢3%) 0 2 (1¢9%) 0¢45
Confusion 1 (1¢3%) 1 (1¢1%) 11 (10¢5%) <0¢01
Drowsiness 7 (9¢3%) 10 (11¢4%) 19 (18¢1%) 0¢10
Renal involvement
Raised creatinine 0 1 (1¢1%) 19 (18¢1%) <0¢01
Acute Kidney Disease 0 3 (3¢4%) 25 (23¢8%) <0¢01
Respiratory Involvement
Cough 11 (14¢7%) 30 (34¢1%) 28 (26¢7%) 0¢02
Tachypnoea 19 (25¢3%) 21 (23¢9%) 48 (45¢7%) <0¢01
CPAP /ventilation / high frequency oscillation 0 3 (3¢4%) 45 (42¢9%) <0¢01
Phenotype class
TSS (N = 39) 0 15 (17¢0%) 24 (22¢9%) <0¢01
KD (N = 24) 0 16 (18¢2%) 8 (7¢6%) <0¢01
PIMS-TS only (N = 216) 75 (100¢0%) 63 (71¢6%) 78 (74¢3%) <0¢01
PIMS-TS/KD (N = 13) 0 10 (11¢4%) 3 (2¢9%) <0¢01
PIMS-TS/TSS (N = 28) 0 9 (10¢2%) 19 (18¢1%) <0¢01
PIMS-TS/Kawasaki/TSS (N = 11) 0 6 (6¢8%) 5 (4¢8%) <0¢01
ALT Alanine transaminase; CPAP Continuous positive airway pressure; IQR Interquartile Range; KD Kawasaki disease; PCR Polymerase chain reaction; PIMS-TS Paedi-
atric Inflammatory Multisystem Syndrome temporally associated with SARS-CoV-2; TSS Toxic shock syndrome.
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